Chiron's Conservative Cash Play
Executive Summary
Two years after selling off its diagnostics business, Chiron has finally decided how to spend some of the money: it bought Pathogenesis for about $700 million. The move brings one small marketed product, and complementary research capacity that promises mostly longer-term benefit for Chiron's interests in infectious diseases. Analysts and investors aren't thrilled by the conservative move, but they're not bailing out either.